SCHEMBL17016129

SCHEMBL17016129

c1ccc(-c2ccc3c4ccc(-c5cccc(-n6ccc7c6ccc6c8ccccc8n(-c8ccccc8)c67)c5)cc4c4ccccc4c3c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
ATM Q13315 2/20 0.40
KDM4E B2RXH2 1/20 0.40
WNK1 Q9H4A3 1/20 0.38
METTL3 Q86U44 1/20 0.34
METTL14 Q9HCE5 1/20 0.34
MAOB P27338 1/20 0.33
TSPO P30536 1/20 0.33
KMT2A Q03164 2/20 0.33
IL1R1 P14778 1/20 0.33
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HTT P42858 2/20 0.32
COMT P21964 2/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
FAAH O00519 1/20 0.31
HSP90AA1 P07900 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17016128 0.99 L3MBTL1 (0.41) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL17016126 0.95 L3MBTL1 (0.40) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL17015187 0.95 ATM (0.36) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL15631999 0.95 L3MBTL1 (0.41) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL16613779 0.95 L3MBTL1 (0.41) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL15802440 0.95 L3MBTL1 (0.44) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL16613856 0.95 L3MBTL1 (0.44) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL17015646 0.94 ATM (0.36) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL17015645 0.94 ATM (0.36) L3MBTL1ATMKDM4EWNK1METTL3
SCHEMBL17015185 0.94 L3MBTL1 (0.41) L3MBTL1ATMKDM4EWNK1METTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885ATM 3623/4885KDM4E 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.